Yan Ruike, Cao Yanli
Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Biomedicines. 2025 Jan 15;13(1):206. doi: 10.3390/biomedicines13010206.
Epigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity. The present review provides a comprehensive summary of the extant clinical findings pertaining to the safety and effectiveness of EGCG in managing obesity and NAFLD, with a particular focus on how treatment duration and dose level affect the bioactivity of this compound.
表没食子儿没食子酸酯（EGCG）是绿茶中主要的生物活性儿茶素，人们认为它对健康有一系列有益影响。目前肥胖率和非酒精性脂肪性肝病（NAFLD）发病率的上升对全球公共卫生构成了持续且沉重的威胁。虽然许多临床研究表明，肥胖和NAFLD患者摄入EGCG后，它对包括代谢生物标志物、腰围和体重在内的各种健康参数有积极影响，但也有一些报告表明它可能有一定程度的肝毒性。本综述全面总结了关于EGCG在治疗肥胖和NAFLD方面的安全性和有效性的现有临床研究结果，特别关注治疗持续时间和剂量水平如何影响该化合物的生物活性。
